ZLDPF Quote, Financials, Valuation and Earnings

Evaxion AS has a net margin of -815.5% compared to Zealand Pharma A/S's net margin of -64.14%. Zealand Pharma A/S's return on equity of 58.28% beat Evaxion AS's return on equity of --.

Zealand Pharma A/S has a consensus price target of --, signalling downside risk potential of -71.81%. On the other hand Evaxion AS has an analysts' consensus of $14.18 which suggests that it could grow by 170%. Given that Evaxion AS has higher upside potential than Zealand Pharma A/S, analysts believe Evaxion AS is more attractive than Zealand Pharma A/S.

Zealand Pharma A/S has a beta of 0.720, which suggesting that the stock is 28.041% less volatile than S&P 500. In comparison Evaxion AS has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Zealand Pharma A/S has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Evaxion AS offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zealand Pharma A/S pays -- of its earnings as a dividend. Evaxion AS pays out -- of its earnings as a dividend.

Zealand Pharma A/S quarterly revenues are $7.8M, which are larger than Evaxion AS quarterly revenues of $37.5K. Zealand Pharma A/S's net income of -$63.3M is lower than Evaxion AS's net income of -$4.9M. Notably, Zealand Pharma A/S's price-to-earnings ratio is 5.74x while Evaxion AS's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zealand Pharma A/S is 4.06x versus 3.52x for Evaxion AS. Usually stocks with elevated PS ratios are considered overvalued.

Genmab A/S has a net margin of -815.5% compared to Zealand Pharma A/S's net margin of 39.24%. Zealand Pharma A/S's return on equity of 58.28% beat Genmab A/S's return on equity of 28.3%.

Zealand Pharma A/S has a consensus price target of --, signalling downside risk potential of -71.81%. On the other hand Genmab A/S has an analysts' consensus of $37.24 which suggests that it could grow by 17.34%. Given that Genmab A/S has higher upside potential than Zealand Pharma A/S, analysts believe Genmab A/S is more attractive than Zealand Pharma A/S.

Zealand Pharma A/S has a beta of 0.720, which suggesting that the stock is 28.041% less volatile than S&P 500. In comparison Genmab A/S has a beta of 0.902, suggesting its less volatile than the S&P 500 by 9.809%.

Zealand Pharma A/S has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Genmab A/S offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zealand Pharma A/S pays -- of its earnings as a dividend. Genmab A/S pays out -- of its earnings as a dividend.

Zealand Pharma A/S quarterly revenues are $7.8M, which are smaller than Genmab A/S quarterly revenues of $1B. Zealand Pharma A/S's net income of -$63.3M is lower than Genmab A/S's net income of $399.2M. Notably, Zealand Pharma A/S's price-to-earnings ratio is 5.74x while Genmab A/S's PE ratio is 13.48x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zealand Pharma A/S is 4.06x versus 5.56x for Genmab A/S. Usually stocks with elevated PS ratios are considered overvalued.

IO Biotech, Inc. has a net margin of -815.5% compared to Zealand Pharma A/S's net margin of --. Zealand Pharma A/S's return on equity of 58.28% beat IO Biotech, Inc.'s return on equity of -297.46%.

Zealand Pharma A/S has a consensus price target of --, signalling downside risk potential of -71.81%. On the other hand IO Biotech, Inc. has an analysts' consensus of $2.46 which suggests that it could grow by 253.57%. Given that IO Biotech, Inc. has higher upside potential than Zealand Pharma A/S, analysts believe IO Biotech, Inc. is more attractive than Zealand Pharma A/S.

Zealand Pharma A/S has a beta of 0.720, which suggesting that the stock is 28.041% less volatile than S&P 500. In comparison IO Biotech, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Zealand Pharma A/S has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IO Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zealand Pharma A/S pays -- of its earnings as a dividend. IO Biotech, Inc. pays out -- of its earnings as a dividend.

Zealand Pharma A/S quarterly revenues are $7.8M, which are larger than IO Biotech, Inc. quarterly revenues of --. Zealand Pharma A/S's net income of -$63.3M is lower than IO Biotech, Inc.'s net income of -$8.4M. Notably, Zealand Pharma A/S's price-to-earnings ratio is 5.74x while IO Biotech, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zealand Pharma A/S is 4.06x versus -- for IO Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Novo Nordisk A/S has a net margin of -815.5% compared to Zealand Pharma A/S's net margin of 26.68%. Zealand Pharma A/S's return on equity of 58.28% beat Novo Nordisk A/S's return on equity of 68.76%.

Zealand Pharma A/S has a consensus price target of --, signalling downside risk potential of -71.81%. On the other hand Novo Nordisk A/S has an analysts' consensus of $53.27 which suggests that it could grow by 11.31%. Given that Novo Nordisk A/S has higher upside potential than Zealand Pharma A/S, analysts believe Novo Nordisk A/S is more attractive than Zealand Pharma A/S.

Zealand Pharma A/S has a beta of 0.720, which suggesting that the stock is 28.041% less volatile than S&P 500. In comparison Novo Nordisk A/S has a beta of 0.670, suggesting its less volatile than the S&P 500 by 32.994%.

Zealand Pharma A/S has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Novo Nordisk A/S offers a yield of 3.61% to investors and pays a quarterly dividend of $0.58 per share. Zealand Pharma A/S pays -- of its earnings as a dividend. Novo Nordisk A/S pays out 35.93% of its earnings as a dividend. Novo Nordisk A/S's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Zealand Pharma A/S quarterly revenues are $7.8M, which are smaller than Novo Nordisk A/S quarterly revenues of $11.7B. Zealand Pharma A/S's net income of -$63.3M is lower than Novo Nordisk A/S's net income of $3.1B. Notably, Zealand Pharma A/S's price-to-earnings ratio is 5.74x while Novo Nordisk A/S's PE ratio is 13.94x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zealand Pharma A/S is 4.06x versus 4.57x for Novo Nordisk A/S. Usually stocks with elevated PS ratios are considered overvalued.